HC.		
	Application No.	Applicant(s)
Notice of Allowability	09/394,019	KOMORIYA ET AL.
	Examiner	Art Unit
	Chih-Min Kam	1653
The MAILING DATE of this communication apper All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate commune GHTS. This application is su	this application. If not included nication will be mailed in due course. THIS
1. \square This communication is responsive to $\underline{1/3/05}$.		
2. The allowed claim(s) is/are <u>1-15</u> .		
3. The drawings filed on 12 April 2004 are accepted by the Examiner.		
 4. ☐ Acknowledgment is made of a claim for foreign priority un a) ☐ All b) ☐ Some* c) ☐ None of the: 		r (f).
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a ENT of this application.	a reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)		ormal Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Sui Paper No./N	mmary (PTO-413), ⁄ail Date <i>20050303</i> .
3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 6/26/03	8), 7. 🛛 Examiner's A	mendment/Comment
4. Examiner's Comment Regarding Requirement for Deposit		Statement of Reasons for Allowance
of Biological Material	9. Other	

Application/Control Number: 09/394,019

Art Unit: 1653

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Tom Hunter on March 2, 2005.

Examiner's Amendments to the Specification:

Please replace the paragraph of the specification beginning at page 1, lines 5-8 with the following paragraph:

This is a continuation-in-part of PCT/US98/0300, filed on February 20, 1998, designating the United States, which is a continuation-in-part of U.S. Application Serial No. 08/802,981, filed on February 20, 1997, now U. S. Patent No. 6,037,137, all of which are herein incorporated by reference in their entirety for all purposes.

Examiner's Amendments to the Claims:

Claims 1 and 9 have been amended as follows:

Claim 1 (Currently amended): A fluorogenic composition for the detection of the activity of a protease, said composition having the formula:

$$F^{1}$$
-aa 1 _j-aa 2 -aa 3 _k-aa 4 _l-aa 5 - X_{m} -P- Y_{n} -aa 6 -aa 7 _o-(aa 8 -aa 9)_p-aa 10 _q- F^{2}
|
(S 1)_i
(S 2)_r

wherein, P has the sequence Leu-Glu-His-Asp-Gly-Ile-Asn (SEQ ID NO:212); $F^1 \text{ and } F^2 \text{ are fluorophores and } F^1 \text{ is attached to the amino terminal amino acid and } F^2 \text{ is attached to the carboxyl terminal amino acid;}$

Application/Control Number: 09/394,019

Art Unit: 1653

 S^1 and S^2 , when present, are peptide spacers ranging in length from 1 to about 50 amino acids and S^1 , when present, is attached to the amino terminal amino acid and S^2 , when present, is attached to the carboxyl terminal amino acid;

i, j, k, l, m, n, o, p, q, and r are independently 0 or 1;

aa¹ and aa¹⁰ are independently selected from the group consisting of lysine, ornithine and cysteine;

aa² and aa³ are independently selected from the group consisting of Asp, Glu, Lys, Ornithine, Arg, Citulline, homocitrulline, Ser, Pro, homoserine, Aib, Thr, and Tyr; aa⁸, and aa⁹ are independently selected from the group consisting of of Asp, Glu, Lys, Ornithine, Arg, Citulline, homocitrulline, Ser, homoserine, Thr, and Tyr; aa⁵, aa⁴, aa⁶, and aa⁷ are independently selected from the group consisting of proline, 3,4-dehydroproline, hydroxyproline, alpha aminoisobutyric acid and N-methyl alanine;

X is selected from the group consisting of Gly, βAla, γAbu, Gly-Gly, Ahx, C7 8-aminocaprylic acid, βAla-Gly, βAla-βAla, γAbu-Gly, βAla-γAbu, Gly-Gly-Gly, γAbu-γAbu, Ahx-Gly, βAla-Gly-Gly, Ahx-βAla, βAla-βAla-Gly, Gly-Gly-Gly-Gly (SEQ ID NO:223), Ahx-γAbu, βAla-βAla-βAla, γAbu-βAla-Gly, γAbu-γAbu-Gly, Ahx-Ahx, γAbu-γAbu-βAla, and Ahx-Ahx-Gly;

Y is selected from the group consisting of Gly, βAla, γAbu, Gly-Gly, Ahx, C7 8-aminocaprylic acid, Gly-βAla, βAla-βAla, Gly-γAbu, γAbu-βAla, Gly-Gly-Gly, γAbu-γAbu, Gly-Ahx, Gly-Gly-βAla, βAla-Ahx, Gly-βAla-βAla, Gly-Gly-Gly-Gly (SEQ ID NO:223), γAbu-Ahx, βAla-βAla-βAla, Gly-βAla-γAbu, Gly-γAbu-γAbu, Ahx-Ahx, βAla-γAbu-γAbu, and Gly-Ahx-Ahx;

when i is 1, S^1 is joined to aa^1 by a peptide bond through a terminal alpha amino group of aa^1 ; and when r is 1, S^2 is joined to aa^{10} by a peptide bond through a terminal alpha carboxyl group of aa^{10} .

Claim 9 (Currently amended): The composition of claim 1, wherein said fluorophore is selected from the group consisting of rhodamine X, 9 (2,5-dicarboxyphenyl) 3,6-bis(dimethylamino)xanthyliumhalide 9-(2,5-dicarboxyphenyl)-3,6-

Application/Control Number: 09/394,019

Art Unit: 1653

bis(dimethylamino)xanthylium halide or other anion, 9-(2,6-dicarboxyphenyl)-3,6-bis(dimethylamino)xanthyliumhalide 9-(2,6-dicarboxyphenyl)-3,6-bis(dimethylamino)xanthylium halide or other anion, 9-(2,5)-dicarboxyphenyl)-2,7-dimethyl-

3,6-bis(ethylamino)xanthylium halide or other anion (Rh6G), 9-(2,6)-dicarboxyphenyl)-2,7-dimethyl-3,6-bis(ethylamino)xanthylium halide or other anion, 9-(2,5-dicarboxyphenyl)-3,6-bisamino-xanthylium halide or other anion (Rh110), 9-(2,6-dicarboxyphenyl)-3,6-bisamino-xanthylium halide or other anion (Rh110), 9-(2,5)-dicarboxyphenyl)-3-amino-6-hydroxy-xanthylium halide or other anion (Blue Rh), 9-(2,6)-dicarboxyphenyl)-3-amino-6-hydroxy-xanthylium halide or other anion (Blue Rh), carboxytetramethylrhodamine, carboxyrhodamine-X, diethylaminocoumarin, 9-(2,5-dicarboxyphenyl)-3,6-bis-(dimethylamino)xanthylium chloride (5-TMR), 9-(2,6-dicarboxyphenyl)-3,6-bis-(dimethylamino)xanthylium chloride (6-TMR), 9-(2-carboxyphenyl)-2,7-dimethyl-3,6-bis(ethylamino)xanthylium, 9-(2-carboxyphenyl)-3,6-bis(dimethylamino)xanthylium, and a carbocyanine dye.

The following is an **Examiner's Statement of Reasons for Allowance**: The following reference appears to be the closest art to the claimed invention. Komoriya *et al.* (U.S. Patent 6,037,137) teach a fluorogenic composition for the detection of the activity of a protease having the formula cited in claim 1, where P is a peptide comprising a protease binding site for the protease, and F^1 and F^2 are fluorophores. The 6,037,137 patent has the same inventors as the instant application, and a terminal disclaimer has been filed. Therefore, the claims are allowable over the art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1653

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D.

MK

Patent Examiner

CMK

March 3, 2005

JON WEBER

SUPERVISORY PATENT EXAMINER